KEYNOTE-522
What it tests: Neoadjuvant pembrolizumab + chemo → adjuvant pembrolizumab for high-risk early TNBC: final analysis
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.